



Correction to: Evaluation of the efficacy of fractional CO₂ laser in the treatment of vulvar and vaginal menopausal symptoms

T. Sindou-Faurie¹ · C. Louis-Vahdat² · E. Oueld Es Cheikh¹ · G. Canlorbe¹ · J. L. Mergui¹ · C. Uzan¹ · H. Azaïs¹

Published online: 7 January 2021

© Springer-Verlag GmbH Germany, part of Springer Nature 2021

Correction to: Archives of Gynecology and Obstetrics
<https://doi.org/10.1007/s00404-020-05868-w>

In the original article published, the table 1 is incorrectly published in a different language. The correct Table 1 is given below.

The original article can be found online at <https://doi.org/10.1007/s00404-020-05868-w>.

✉ H. Azaïs
henriazais@gmail.com

¹ Department of Gynecologic and Breast Surgery and Oncology, AP-HP, Hôpitaux Universitaires Pitié Salpêtrière-Charles Foix, 47-83 boulevard de l'hôpital, 75013 Paris, France

² Medicine Cabinet, 126 boulevard Saint-Germain, 75006 Paris, France

Table 1 Patients characteristic and previous therapy for genitourinary syndrome of menopause

	Total (n=46)	University Hospital (n=32)	Medicine cabinet (n=14)	P
Age (years): mean ± SD	57.3 ± 11.1	57.4 ± 13.5	57.3 ± 10.2	0.958
Weight (kg): mean ± SD	62.4 ± 14.2	68.7 ± 14.4	52.3 ± 5.5	0.0004
Height (cm): mean ± SD	163.1 ± 8.1	164.7 ± 8.2	161.5 ± 8.1	0.343
BMI (kg/m ²): mean ± SD	23.2 ± 4.7	25 ± 4.7	20.2 ± 3.2	0.003
Menopause: n (%)	40 (87.0%)	30 (93.8%)	12 (85.7%)	0.574
MHT use: n (%)	14 (30.4%)	7 (21.9%)	7 (50%)	0.084
Local hormone therapy use: n (%)	20 (43.5%)	13 (40.6%)	7 (50%)	0.748
Hyaluronic acid use: n (%)	11 (23.9%)	5 (15.6%)	6 (42.9%)	0.065
Lubricant use: n (%)	23 (50%)	11 (34.4%)	12 (85.7%)	0.003
Breast cancer: n (%)	13 (28.3%)	13 (40.6%)	0 (0%)	0.004
Pelvic cancer: n (%)	5 (10.9%)	4 (12.5%)	1 (7.1%)	1
Pelvic radiation therapy: n (%)	3 (6.5%)	2 (6.3%)	1 (7.1%)	1
Breast radiation therapy: n (%)	11 (23.9%)	11 (34.4%)	0 (0%)	0.020
Chemotherapy: n (%)	11 (23.9%)	10 (31.3%)	1 (7.1%)	0.133
Hormone therapy: n (%)	10 (21.7%)	10 (31.3%)	0 (0%)	0.020
Premature ovarian failure: n (%)	3 (6.5%)	3 (9.4%)	0 (0%)	0.543

SD standard deviation, BMI body mass index, MHT menopausal hormone therapy

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.